Other Events ·
Anika Therapeutics held its Annual Meeting of Stockholders on June 18, 2026, with 84.14% of voting power represented
ANIKAnika Therapeutics, Inc.
Anika Therapeutics held its Annual Meeting of Stockholders on June 18, 2026, with 84.14% of voting power represented. Stockholders elected Gary P. Fischetti, John B. Henneman, III, and Stephen D. Griffin as Class III directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026. Shareholders approved the Revised Seventh Amended 2017 Omnibus Incentive Plan, which increases the common stock reserve from 5,760,000 to 6,110,000 shares. Additionally, stockholders approved an amendment to the 2021 Employee Stock Purchase Plan, doubling the reserved shares from 200,000 to 400,000. The company operates in the biotechnology industry, focusing on regenerative medicine.